Origin Materials, a leading carbon negative materials company with a mission to enable the world’s transition to sustainable materials, started the commercial-scale production at Origin 1, located in Sarnia, Ontario, Canada, the first commercial plant of its kind.
Origin Materials, California-headquartered carbon negative materials company with a mission to enable the world’s transition to sustainable materials, began startup of Origin 1, the world’s first commercial CMF plant, located in Sarnia, Ontario, in-line with prior guidance.
Bioindustrial Innovation Canada (BIC) has made a COMM SCI (Centre for Commercialization of Sustainable Chemistry Innovation) investment, whose amount wasn’t disclosed, in Origin Materials through BIC’s Sustainable Chemistry Alliance (SCA) investment fund, as part of an investment round that will see Origin construct its first commercial scale demonstration facility in Sarnia (Ontario) by late 2018.
“The bioeconomy is an important piece of the puzzle in creating a more sustainable future”. To say it – in this exclusive interview with Il Bioeconomista – is Andrew Richard, founder, chairman and Chief Technology Officer of Comet Biorefining, a Canadian provider of sustainable cellulosic glucose technology for applications in renewable biofuels and biochemical. With Richard, who received his B.E.Sc. degree in Chemical and Biochemical Engineering from The University of Western Ontario in 1990, an M.B.A. from the Richard Ivey School of Business in 1993, we talk about his company and the bioeconomy in Canada.
Interview by Mario Bonaccorso
Mitsui & Co., one of the most diversified and comprehensive trading, investment, and service enterprises in the world (with 140 offices in 66 countries) and BioAmber’s partner in the Sarnia bio-based succinic acid plant, is investing an additional CDN$ 25 million in the joint venture for 10% of the equity, increasing its stake from 30% to 40%. Mitsui will also play a stronger role in the commercialization of bio-succinic acid produced in Sarnia, providing dedicated resources alongside BioAmber’s commercial team. BioAmber will maintain a 60% controlling stake in the joint venture.
IL BIOECONOMISTA 